Scancell is initiating a collaborative research project that aims to use its oncology vaccine expertise to develop a second generation COVID-19 vaccine. Its DNA vaccine technologies target dendritic cells and have proven ability to stimulate high avidity and potent T cell responses. The objective is to produce a simple, safe, cost-effective, and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies to SARS-CoV-2 infection. Subject to funding, including non-dilutive grants from governments, a candidate vaccine could enter Phase I trials in Q121. Scancell's primary focus remains on developing its innovative immuno-therapies for cancer, as detailed in our May 2020 Outlook. The early nature of the COVID-19 project means that we currently do not include it in our £72.4m (15.6p/share) Scancell valuation.
11 May 2020
COVID 2nd generation vaccine opportunity is all upside
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
COVID 2nd generation vaccine opportunity is all upside
Scancell Holdings Plc (SCLP:LON) | 9.6 0 0.5% | Mkt Cap: 89.1m
- Published:
11 May 2020 -
Author:
Lala Gregorek -
Pages:
7
Scancell is initiating a collaborative research project that aims to use its oncology vaccine expertise to develop a second generation COVID-19 vaccine. Its DNA vaccine technologies target dendritic cells and have proven ability to stimulate high avidity and potent T cell responses. The objective is to produce a simple, safe, cost-effective, and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies to SARS-CoV-2 infection. Subject to funding, including non-dilutive grants from governments, a candidate vaccine could enter Phase I trials in Q121. Scancell's primary focus remains on developing its innovative immuno-therapies for cancer, as detailed in our May 2020 Outlook. The early nature of the COVID-19 project means that we currently do not include it in our £72.4m (15.6p/share) Scancell valuation.